Yoseph Jeffry Hertanto


About 10 million people in Indonesia have been impacted by heart failure (HF), which is a complex clinical syndrome caused by insufficient cardiac output that is unable to meet the body's metabolic needs. The most frequent kind of HF, heart failure with preserved ejection fraction (HFpEF), has the fewest available treatments. Diuretics and SGLT-2 Inhibitors are the first-line treatments for HFpEF. This paper aim to determine the mechanism of sodium-glucose cotransporter-2 (SGLT-2) Inhibitors in HFpEF and the newest recommendation for it, so that it might be utilized as a reference for management in the future. This is a literature review study which conducting by gathering numerous books and journal articles which relevant with the topic. The mechanisms of SGLT-2 Inhibitors in HFpEF are not well understood, but some theories suggest that these medications affect preload, afterload, cardiac remodeling, blood pressure, arterial stiffness, and ketone body formation. They can also stimulate erythropoiesis, inhibit the myocardial Na+/H+ exchanger (NHE), and have anti-oxidant and anti-inflammatory effects, so they are no longer just seen as anti-diabetic medications. Recently, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) published a Heart Failure guidelines and classify SGLT-2 Inhibitors as a class IB treatment for HFpEF.

Save to Mendeley


SGLT-2 Inhibitors; HFpEF; EMPEROR-Preserved; DELIVER; PERKI

Full Text:



Putra MGD, Laksono S. Sodium Glucose Co-Transporter-2 (SGLT 2) Inhibitor as A Therapy For Heart Failure With Low Ejection Fraction (HFrEF). FITOFARMAKA J Ilm Farm [Internet]. 2022 Dec 30;12(2):148–55. Available from:

Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition o. J Card Fail. 2021;27(4):387–413.

Nauli SE, Prima Putri VK, Arifianto H, Prameswari HS, Lubis AC, Zulkarnain E, et al. Heart Failure With Preserved Ejection Fraction: Current Status of Daily Clinical Practice in Indonesia. Cureus. 2023;15(4):1–12.

Lu Y, Li F, Fan Y, Yang Y, Chen M, Xi J. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials. Eur J Intern Med [Internet]. 2021 May;87(March):20–8. Available from:

Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol [Internet]. 2014;171(3):368–76. Available from:

McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al. A trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21(5):665–75.

Pfeffer MA, Shah AM, Borlaug BA. Heart Failure with Preserved Ejection Fraction in Perspective. Circ Res. 2019;124(11):1598–617.

Reddy YNV, Rikhi A, Obokata M, Shah SJ, Lewis GD, AbouEzzedine OF, et al. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail. 2020;22(6):1009–18.

Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. Int J Hear Fail. 2023;5(2):82.

Yang D, Zhang Y, Yan J, Liu M, An F. SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. Front Cardiovasc Med. 2022;9.

Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman Tatalaksana Gagal Jantung. Third Edit. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2023. 101 p.

Kounatidis D, Vallianou N, Evangelopoulos A, Vlahodimitris I, Grivakou E, Kotsi E, et al. SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? Nutrients. 2023;15(10):1–16.

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148–58.

Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol. 2021;83:503–28.

Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol [Internet]. 2020;17(12):761–72. Available from:

Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326–36.

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–61.

Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019;21(10):1279–87.

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–98.

Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol [Internet]. 2017;14(10):591–602. Available from:

Lam CSP, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18–28.

Caparrotta TM, Greenhalgh AM, Osinski K, Gifford RM, Moser S, Wild SH, et al. Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Ther [Internet]. 2021;12(4):991–1028. Available from:

Vallianou NG, Christodoulatos GS, Kounatidis D, Dalamaga M. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem. Metab Open. 2021;10:100089.

Kang A, Jardine MJ. SGLT2 inhibitors may offer benefit beyond diabetes. Nat Rev Nephrol [Internet]. 2021;17(2):83–4. Available from:

Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic to Transl Sci. 2020;5(6):632–44.

Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation. 2020;142(11):1028–39.

Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial. Circulation. 2020;142(18):1713–24.

Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422–34.

Dekkers CCJ, Sjöström CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes, Obes Metab. 2019;21(12):2667–73.

Verma S. Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits. Am J Cardiol [Internet]. 2019;124(10):S36–44. Available from:

Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6).

Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, et al. Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can J Cardiol [Internet]. 2020;36(4):543–53. Available from:

Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med [Internet]. 2017;104(December 2016):298–310. Available from:

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol. 2019;73(15):1931–44.

García-Ropero Á, Vargas-Delgado AP, Santos-Gallego CG, Badimon JJ. Inhibition of sodium glucose cotransporters improves cardiac performance. Int J Mol Sci. 2019;20(13):8–10.

Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, et al. Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors. JACC Basic to Transl Sci. 2018;3(5):575–87.

Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al. Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from the EMBRACE-HF Trial. Circulation. 2021;143(17):1673–86.

Fukuta H, Hagiwara H, Kamiya T. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. IJC Hear Vasc [Internet]. 2022 Oct;42(11):101103. Available from:

Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, et al. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation. 2020;141(8):704–7.

Baartscheer A, Schumacher CA, Wüst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–73.

Williams DM, Evans M. Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. Diabetes Ther. 2020;11(9):1925–34.

Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–71.

Masson W, Lavalle-Cobo A, Nogueira JP. Effect of sglt2-inhibitors on epicardial adipose tissue: A meta-analysis. Cells. 2021;10(8):1–10.

Samaan K, Wagdy K. DELIVER: Extending the benefits of SGLT-2 inhibitors. Glob Cardiol Sci Pract. 2023;2023(3).

Baratto C, Caravita S, Soranna D, Dewachter C, Bondue A, Zambon A, et al. Exercise haemodynamics in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Hear Fail. 2022;9(5):3079–91.

Al-Abdouh A, Mhanna M, Barbarawi M, Abusnina W, Gupta VA. A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction. Am J Cardiol [Internet]. 2022 Feb;164:138–41. Available from:

Pandey AK, Dhingra NK, Hibino M, Gupta V, Verma S. Sodium-glucosecotransporter 2 inhibitors in heart failure with reduced or preserved ejectionfraction: a meta-analysis. ESC Hear Fail. 2022;9(2):942–6.

Singh AK, Singh R. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr Clin Res Rev. 2021;15(1):351–9.

Mascolo A, Di Napoli R, Balzano N, Cappetta D, Urbanek K, De Angelis A, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front Cardiovasc Med. 2022;9.

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis. Diabetes, Obes Metab [Internet]. 2019 May 4;21(5):1237–50. Available from:

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764–9.

FDA. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. FDA, Saf Announc [Internet]. 2018;1–6. Available from:

Baigent C, Emberson J, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet [Internet]. 2022 Nov;400(10365):1788–801. Available from:

Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129–39.

McDonagh TA, Metra M, Adamo M, Baumbach A, Böhm M, Burri H, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Vol. 145, Circulation. 2022. 895–1032 p.